← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aquilus Pharmaceuticals, Inc.
Winchester, MA
$4,523,387
Total funding
7
Grants
Funding over time
peak $1.4M · FY2011–22$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,562,237 · 6
DOD$961,150 · 1
By mechanism
R44$1,931,422 · 1
R43$1,630,815 · 5
—$961,150 · 1
Investigators at Aquilus Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of a MMP Inhibitor for Neuropathic Pain$1,375,173
R44 · FY2016 · DE
MATRIX METALLOPROTEINASE INHIBITOR FOR THE TREATMENT OF ALS$961,150
· FY2022 · Defense Health Agency
Development of a MMP Inhibitor for Neuropathic Pain$556,249
R44 · FY2015 · DE
Matrix Metalloproteinase-2/-9 Inhibitor For The Treatment Of ALS$457,639
R43 · FY2019 · NS
Selective Matrix Metalloproteinase Inhibitors For Osteoarthritis$373,995
R43 · FY2012 · AG
Orally active MMP inhibitor for the treatment of bone cancer pain$287,199
R43 · FY2015 · CA
Metalloproteinase Inhibitor For Pain and Morphine Tolerance Due To Thermal Injury$261,982
R43 · FY2014 · GM
MMP Inhibitor For Orofacial Pain$250,000
R43 · FY2011 · DE